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Abstract
Objective To assess the efficacy and safety of enzyme re-
placement therapy (ERT) with BMN 110 (elosulfase alfa) in
patients with Morquio A syndrome (mucopolysaccharidosis
IVA).
Methods Patients withMorquio A aged ≥5 years (N=176) were
randomised (1:1:1) to receive elosulfase alfa 2.0 mg/kg/every
other week (qow), elosulfase alfa 2.0 mg/kg/week (weekly) or
placebo for 24 weeks in this phase 3, double-blind, randomised
study. The primary efficacy measure was 6-min walk test
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(6MWT) distance. Secondary efficacy measures were 3-min
stair climb test (3MSCT) followed by change in urine keratan
sulfate (KS). Various exploratory measures included respiratory
function tests. Patient safety was also evaluated.
Results At week 24, the estimated mean effect on the 6MWT
versus placebo was 22.5 m (95 % CI 4.0, 40.9; P=0.017) for
weekly and 0.5 m (95 % CI −17.8, 18.9; P=0.954) for qow.
The estimated mean effect on 3MSCT was 1.1 stairs/min
(95 % CI −2.1, 4.4; P=0.494) for weekly and −0.5 stairs/
min (95 % CI −3.7, 2.8; P=0.778) for qow. Normalised urine
KS was reduced at 24 weeks in both regimens. In the weekly
dose group, 22.4 % of patients had adverse events leading to
an infusion interruption/discontinuation requiring medical in-
tervention (only 1.3 % of all infusions in this group) over
6 months. No adverse events led to permanent treatment
discontinuation.
Conclusions Elosulfase alfa improved endurance as measured
by the 6MWT in the weekly but not qow dose group, did not
improve endurance on the 3MSCT, reduced urine KS, and had
an acceptable safety profile.
Introduction
Morquio A syndrome (mucopolysaccharidosis [MPS] IVA;
OMIM 253000) is a rare autosomal recessive lysosomal stor-
age disorder caused by a deficiency in the enzyme N-
acetylgalactosamine-6-sulfatase (GALNS; EC 3.1.6.4). This
enzyme deficiency leads to an impaired degradation of the
glycosaminoglycans (GAGs) keratan sulfate (KS) and
chondroitin-6-sulfate (C6S) (Neufeld and Muenzer 2001).
The incidence of Morquio A syndrome ranges from 1 in
640,000 live births in Western Australia to 1 in 76,000 live
births in Northern Ireland (Nelson 1997; Nelson et al 2003).
Patients with Morquio A appear healthy at birth, but pro-
gressively develop a variety of clinical manifestations associ-
ated with the excessive GAG storage in tissues and organs and
disruption in cellular processes (Yasuda et al 2013). The
disease progression rate and the severity of clinical manifes-
tations vary between patients. Typical clinical manifestations
of Morquio A patients are profound skeletal dysplasia includ-
ing dwarfism with short trunk and neck, spinal abnormalities,
pectus carinatum, genu valgum, hip dysplasia, joint hypermo-
bility and instability due to ligamentous laxity and bone
deformities at the joint (Harmatz et al 2013; Neufeld and
Muenzer 2001). In the longitudinal, prospective Morquio A
Clinical Assessment Program (MorCAP) study including data
from 325 Morquio A patients, over 90 % of patients showed
skeletal dysplasia (Harmatz et al 2013). Other characteristic
manifestations of the disease include dental abnormalities,
spinal cord compression and myelomalacia, breathing diffi-
culties due to airway obstruction and/or restrictive pulmonary
disease, cardiac valve disease, impaired vision (e.g. corneal
clouding, glaucoma), hearing loss and hepatosplenomegaly
(Harmatz et al 2013; Hendriksz et al 2013; Neufeld and
Muenzer 2001). Death commonly occurs due to cardiorespi-
ratory or neurological complications (Harmatz et al 2013).
Patients with a rapidly progressing phenotype generally die
in their second or third decade of life (Harmatz et al 2013;
Montaño et al 2007). Slowly progressing patients generally
show less severe skeletal manifestations than those with a
rapidly progressing course, but typical physical symptoms
appear later in life and patients rarely survive beyond the sixth
decade of life (Harmatz et al 2013).
Until recently, there was no approved treatment for
Morquio A syndrome other than supportive care. Enzyme
replacement therapy (ERT) with recombinant human
represents a new treatment option that was approved in the US
by the Food and Drug Administration in February 2014.
Elosulfase alfa is expected to increase KS and C6S catabolism
and reduce the KS and C6S accumulation contributing to the
clinical manifestations.
Elosulfase alfa is produced in a genetically engineered
Chinese Hamster Ovary (CHO) mutant cell line that expresses
the cDNA encoding for the full human GALNS protein. It is
identical to the naturally occurring human lysosomal enzyme
in terms of the amino acid sequence and N linked glycosyla-
tion sites. rhGALNS is a soluble dimeric protein and each
monomer contains 496 amino acids (after cleavage of the
signal peptide) with a calculated isotope average molecular
mass of 55 kDa for the peptide chain. The nonclinical phar-
macology, pharmacokinetics and toxicology of elosulfase alfa
have been evaluated in several in vitro and in vivo animal
studies (Dvorak-Ewell et al 2010 and unpublished results),
showing a toxicological and safety profile consistent with that
observed in the nonclinical programs of other ERTs. The
combined nonclinical data supported the clinical use of
elosulfase alfa at the proposed dose and interval of 2 mg/kg/
week via 4 h intravenous (iv) infusions for Morquio A pa-
tients. Further insights about the clinical efficacy and safety of
elosulfase alfa were previously provided in a multicentre,
phase 1/2, open-label, dose-escalation study including 20
Morquio A patients aged 5–18 years. Measures of 6-min walk
test [6MWT], 3-min stair climb test [3MSCT]) and respiratory
function were generally improved with elosulfase alfa
1.0 mg/kg/week and 2.0 mg/kg/week doses. Mean improve-
ments over baseline were sustained after approximately
2 years, although there was no long-term control, there were
missing data, and effort-dependent endpoints were evaluated
in an open-label setting (Hendriksz et al 2012). In addition,
urinary KS levels decreased, with the lowest levels occurring
during dosing with the 2.0 mg/kg/week regimen.
The present phase 3 study was designed to assess the
efficacy and safety of two dosing regimens of elosulfase alfa
infusions in comparison with placebo in Morquio A patients.
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Materials and methods
Study design
This was a multinational, multicentre, double-blind,
randomised, placebo-controlled, 24-week phase 3 study
(#NCT01275066). The study was conducted by 34 principal
investigators at 33 study centres in 17 countries. A schematic
presentation of the study design is shown in Supportive online
material 1. After screening, eligible patients completed base-
line assessments and were randomised to receive infusions of
elosulfase alfa 2.0 mg/kg/week, elosulfase alfa 2.0 mg/kg/
every other week (qow) or placebo for a period of 24 weeks.
Randomisation was stratified by screening 6MWT category
(≤200 and >200 m) and age group (5–11, 12–18, ≥19 years
old). Patients, investigators and site personnel were blinded to
treatment assignment throughout the study and until the final
analysis was complete. All patients completing the first
24 weeks of the study were eligible for enrolment in an
extension study.
Patient selection
Study participants ≥5 years of age had a clinical diag-
nosis of Morquio A syndrome based on clinical signs
and symptoms of the disease and documented reduced
fibroblast or leukocyte GALNS enzyme activity or ge-
netic testing confirming the diagnosis. Participants were
also required to have an average 6MWT distance ≥30
and ≤325 m during screening, and had to be willing to
use an acceptable method of contraception during the
study (if sexually active). Patients who had previous
hematopoietic stem cell transplantation, previous treat-
ment with elosulfase alfa, major surgery within 3 months
of study entry or planned surgery during the 24-week
study treatment period, were pregnant or breastfeeding
at screening or planning to become pregnant (self or
partner) during the study, were using any investigational
product or medical device within 30 days before screen-
ing or during the study, or had concurrent morbidity
that would interfere with study participation or safety
(e.g. symptomatic cervical spine instability, clinically
significant spinal cord compression, severe cardiac dis-
ease) or that could interfere with treatment compliance
were excluded from the study.
The rationale for including limits for baseline 6MWT dis-
tance of 30 to 325 m was to identify patients most likely to
show improvement, i.e. excluding severely walk impaired
patients with disease that has progressed to a point where
walk impairment may not be reversible, and excluding those
with walk distance approaching the normal range to avoid the
potential for a ceiling effect.
Study drug administration
Patients were pre-treated (approximately 30 to 60 min before
each study drug infusion) with an antihistamine (preferably
non-sedating, such as cetirizine or loratadine). Mandatory pre-
treatment with anti-histamines was instituted during the prior
phase 1/2 study and all subsequent studies to reduce the risk of
infusion-associated reactions (IARs), which are to be expected
upon infusion of large amounts of protein in general and based
on previous experience with other ERTs. A sedating antihis-
tamine or premedication with additional agents, such as H2
blockers, leukotriene receptor antagonists, steroids and/or an-
tipyretic medications could be administered to patients with
known risk factors for IARs, such as a history of IARs or
allergies. IARs were defined as any adverse events (AEs)
(regardless of drug relationship) that occurred after infusion
onset and within 1 day after infusion end. Elosulfase alfa
(2.0 mg/kg) or placebo solution was diluted with saline to a
total volume of up to 250 mL at room temperature and
administered iv. Patients randomised to elosulfase alfa
2.0 mg/kg/qow received infusions of placebo on alternating
weeks to mask active drug weeks. Each infusion was admin-
istered over a period of approximately 4 h. For a volume of
100 mL, infusion rates were 3 mL/h for the first 15 min, then
6 mL for 15 min, then 6 mL increases every 15 min until a
final rate of 36 ml/h until completed. For a volume of 250 mL,
infusion rates were 6 mL/h for the first 15 min, then 12 mL for
15 min, then 12 mL increases every 15 min until a finale rate
of 72 mL/h until completed.
Efficacy evaluation
The primary efficacy measure was the distance walked in a
6MWT, which provides a measure of endurance. The 6MWT
was performed according to American Thoracic Society
(ATS) Guidelines (American Thoracic Society 2002).
Secondary efficacy variables were 3MSCT, another measure
of endurance, followed hierarchically by normalised urine KS.
The 3MSCTwas performed as previously described (Harmatz
et al 2005). Both the 6MWT and 3MSCT were conducted
twice on separate days at screening, week 12, and week 24 and
within 1 week of early withdrawal from the study. Patients
who were physically unable to perform the tests were scored
as zero meters or stairs/min. The walk test score for each visit
week was the average of the two measurements conducted for
each time point. Study site personnel were thoroughly trained
and certified in order to minimise variability in the conduct of
the 6MWT and 3MSCT. Urine KS and creatinine were mea-
sured by quantitative analysis of samples obtained from first
morning voids on two separate days at baseline and a single
morning void at weeks 2 and 4 and every 4 weeks thereafter,
as well as within 1 week of early withdrawal. A selective,
sensitive and precise LC-MS/MS assay was used to measure
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the KS-derived disaccharides (Martell et al 2011). Urine KS
concentrations normalised to creatinine concentrations were
calculated.
Tertiary measures included pulmonary function measures
such as forced vital capacity (FVC), forced expiratory volume
in 1 s (FEV1) and maximum voluntary ventilation (MVV)
conducted according to ATS guidelines (American Thoracic
Society 1995). MVV results were included in a composite
efficacy measure comprised of the average of the 24-week
changes from baseline in normalised 6MWT, 3MSCT and
MVV components. Each of the 6MWT, 3MSCT and MVV
results were normalised as a z-score, using the calculated
mean and standard deviation of all non-missing baseline
scores as the reference. The composite measure was based
on an equal weighting of week 24 change from baseline of the
three component z-scores.
A number of additional tests and measures were included
for exploratory purposes such as anthropometric measures
(standing height, growth rate, sitting height, length and
weight), hearing (measured using audiometry), cardiac valve
function on echocardiogram, corneal clouding (as assessed by
physical examination) and radiographic examinations (of cer-
vical and lumbar spine; for subjects ≤20 years, lower extrem-
ity radiographs). Biochemical markers of inflammation (tu-
mor necrosis factor α [TNFα]) and bone and cartilage metab-
olism (C-terminal crosslinked C-telopeptide [CTX1] and type
IIA collagen N-propeptide [PIIANP]) were also determined.
Quality of life (QoL) was assessed using the MPS Health
Assessment Questionnaire (HAQ) which was originally de-
veloped to assess the self-care and mobility skills of patients
with MPS I, and is currently used in an international MPS I
Registry: (https://www.lsdregistry.net/mpsiregistry/hcp/
partic/mreg_hc_p_healthassess.asp).
Safety evaluation
Safety was assessed by examining incidence, severity and
relationship to study drug of treatment-emergent AEs reported
during the study. In addition, IARs, laboratory results
(haematology, blood chemistry, urinalysis, thyroid function),
vital signs, electrocardiogram and echocardiogram at screening
and week 24, physical examination, concomitant medications
and immunogenicity were assessed. Immunogenicity tests
were performed using standardized immunogenicity assays
on blood samples collected prior to study drug infusion at
baseline and at weeks 2, 4, 8, 12, 16, 20 and 24. The total
antibody assay measured multiple anti-drug antibody isotypes
in one assay. Immunogenicity tests included elosulfase alfa-
specific total antibody (TAb), neutralizing antibody (Nab, that
inhibit cellular receptor binding), elosulfase alfa-specific im-
munoglobulin (Ig) E; and total IgE (baseline only). When TAb
was negative, NAb was not assessed. Subjects with a severe
IAR or IAR requiring infusion cessation had an additional
blood sample taken to assess total IgE, drug specific IgE levels,
complement, and tryptase. Potential hypersensitivity AEs were
identified by utilising the broad Anaphylactic Reaction algo-
rithmic Standardized Medical Dictionary of Regulatory
Activities (MedDRA) query (SMQ) (MedDRA, version 15.0,
http://www.meddra.org/) and the broad Angioedema SMQ.
Statistical methods
It was calculated that approximately 162 subjects (54 subjects
in each group) were to be enrolled into the study to have over
90 % power to detect a difference of 40 m in mean change in
the 6MWT distance between the elosulfase alfa groups and
the placebo group, assuming that the common standard devi-
ation is 65 m with an overall 0.05 two sided significance level
with Hochberg method for multiplicity adjustment.
The modified intent-to-treat efficacy analyses included all
subjects who were randomised to study treatment and re-
ceived at least one dose of study drug. The primary efficacy
endpoint was the change from baseline at week 24 in the
6MWT distance. As the primary analysis method, the change
in 6MWT distance from baseline to week 24 was compared
between the placebo group and the elosulfase alfa 2.0 mg/kg/
week and the elosulfase alfa 2.0 mg/kg/qow-treated groups
separately, using an analysis of covariance (ANCOVA) model
with baseline 6MWT category (≤200 and >200 m) and age
group (5–11, 12–18, ≥19 years) as the covariates. As a sup-
portive analysis, a cumulative distribution function of change
from baseline at week 24 in 6MWTwas plotted by treatment
group. Exploratory analyses were performed to obtain clues
about whether treatment effects differed across the levels of
several baseline covariates, including the screening 6MWT,
age categories, sex, race and region. The secondary endpoints
(change from baseline at week 24 in the number of stairs
climbed per minute in the 3MSCTand in the normalised urine
KS) and additional supportive endpoints were analysed sim-
ilarly to the 6MWT. As an adjustment for multiplicity with the
secondary endpoints, a step-down testing procedure was used.
The results of the 3MSCTwere tested first, and the urine KS
results could only be declared significant if the 3MSCT
showed a significant result due to the requirement of the pre-
specified statistical analysis plan. For the primary and second-
ary endpoints, the Hochberg method for multiplicity adjust-
ment was used for the two treatment comparisons with place-
bo (Hochberg 1988). There was only one subject with missing
data points for 6MWT at 24 weeks. Multiple imputation was
used in the primary analysis of primary, secondary and respi-
ratory function test endpoints (Rubin 1987) when a measure-
ment was not available. The imputation was based on the joint
normal distribution for the endpoint at all scheduled assess-
ments, baseline age and baseline 6MWT scores.
Safety analysis included all patients who received any
study drug (either elosulfase alfa or placebo) throughout the
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study duration. The incidence rates for AEs were summarised
by System Organ Class, Preferred Term, relationship to study
drug and severity for each treatment group.
Results
Patient characteristics
Of the 204 patients who were screened, 177 were randomised.
One randomised patient was not dosed and excluded from all
analyses because the diagnosis of Morquio A syndrome was
not confirmed. Of the 176 patients, 59 were randomised to
placebo, 59 to elosulfase alfa 2.0 mg/kg/qow and 58 to
elosulfase alfa 2.0 mg/kg/week; 175 patients completed the
study. One patient in the elosulfase alfa 2.0 mg/kg/week
population discontinued after the first infusion due to with-
drawal of consent. The withdrawal was due to logistic diffi-
culties for attending study visits and not because of safety
concerns.
All treatment groups achieved high mean dosing compli-
ance (range 96.8 to 99.2 %) and few efficacy data points were
missing. Baseline demographics and clinical characteristics of
the patients are listed in Supportive online material 2, showing
a broad distribution of ages ranging from 5 to 57 years (me-
dian age 11.9 year), races and ethnicity and an equal repre-
sentation between genders (54.2 % females). There were no
meaningful imbalances between treatment groups at baseline
in demographic and baseline characteristics. 6MWT distance
ranged from 36 to 322 m.
The entry criteria for 6MWTand the mean baseline 6MWT
distance of 210 m confirm that patients were significantly
impaired in endurance/mobility. Patients showed a wide varia-
tion in their functional impairment and organ system involve-
ment. Medical history findings were similarly distributed across
treatment groups and reflected the serious morbidities that
Morquio A patients experience (Supportive online material 3).
At least one abnormal medical history finding was reported for
≥98.3 % of patients in each group, with knee deformity, corneal
opacity and pectus carinatum being most common.
Primary efficacy measure: 6MWT
The primary efficacy outcome at week 24 was evaluated using
ANCOVA model based analysis (Table 1). The estimated
mean effect on the 6MWT versus placebo was 22.5 m
(95 % CI 4.0, 40.9; P=0.017) for the elosulfase alfa
2.0 mg/kg/week regimen, and 0.5 m (95 % CI −17.8, 18.9;
P=0.954) for the elosulfase alfa 2.0 mg/kg/qow regimen.
Accounting for the pre-specified adjustment for comparison
of both regimens with placebo, the effect on the weekly
regimen did meet the threshold for statistical significance
(P=0.017<0.025) for the primary end point of the trial.
Figure 1a shows the least-square mean change from baseline
over time for the placebo and treatment groups. Elosulfase alfa
2.0 mg/kg/week improved walking distance, relative to place-
bo, by 11 m at week 12 and by 23 m at week 24 (Supportive
online material 4). The estimated cumulative distribution
function in the placebo and elosulfase alfa treatment groups
is provided in Fig. 1b.
Sensitivity analyses for effects on 6MWT were con-
sistent with the primary analysis. The sensitivity analy-
ses included analysis of the first, second and best of the
duplicate measurements performed on two separate days
at each visit. Analyses omitting outliers and using alter-
native methods for handling missing observations in-
cluding observed cases were also performed. There were
very few missing observations. Subgroup analyses did
not provide strong evidence of effect modification by
any of the categories of age group, sex, race and geo-
graphic region (see Supportive online material 5).
However, there was a trend for larger effects on
6MWT in patients with baseline 6MWT≤200 m and
for smaller effects in patients with baseline 6MWT>
200 m.
Secondary and tertiary measures
On the 3MSCT (stairs/min), the elosulfase alfa 2.0 mg/kg/
week group showed a small numerical increase and elosulfase
alfa 2.0 mg/kg/qow group showed a small numerical decrease
as compared to placebo, without statistical significance
(Table 1, Supportive online material 6).
Given the hierarchical analysis of the secondary endpoints
(with the 3MSCT tested first and not reaching statistical
significance), the results for the remaining secondary and
tertiary endpoints are presented in a descriptive manner in
Table 1. P-values of these endpoints are provided in
Supportive online material 7.
Treatment with elosulfase alfa led to an estimated reduction
in urine KS in both treatment arms (Fig. 2), specifically being
−30.2 % for the qow dosing regimen and −40.7 % for the
weekly dosing regimen (Table 1) when compared with place-
bo at week 24.
For the tertiary variable MVV, numerical improvement
favouring the elosulfase alfa regimens were seen when com-
pared to placebo. Regarding the composite score combining
6MWT, 3MSCTand MVV z-scores at week 24, the estimated
treatment effect at week 24 versus placebo was 0.1 (95 % CI
−0.0, 0.3) for elosulfase alfa 2.0 mg/kg/week and 0.0 (95 %CI
−0.1, 0.2) for elosulfase alfa 2.0 mg/kg/qow (Table 1).
For the other exploratory measures, treatment with
elosulfase alfa (both dosing regimens) led to small to modest
differences that were in the positive direction for the majority,
though with wide confidence intervals. These measures in-
clude FVC, FEV1, QoL (Caregiver Assistance Domain and
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Mobility Domain scores of the MPS HAQ), standing
height and growth rate z-scores in males ≤18 years and
females ≤15 years (Table 1). Differences in audiometry,
echocardiogram, corneal clouding, or lower extremity
bone length were small. Given the limited duration of
the trial and the natural history of Morquio A syn-
drome, statistically precise estimates of effects on these
measures were unlikely to be achieved. Elosulfase alfa
treatment also was not associated with a reduction in
the blood inflammatory marker TNFα or changes in
Table 1 The effect of elosulfase alfa on primary, secondary and tertiary efficacy endpoints (intent-to-treat population). Modelled treatment effect,
defined as (change from baseline to week 24, elosulfase alfa)–(change from baseline to week 24, Placebo)
Modelled treatment effecta 2.0 mg/kg/qow vs. placebo (N=59 vs. 59) 2.0 mg/kg/week vs. placebo (N=58 vs. 59)
Primary outcome
6MWT distance (meters change from BL)
LS Mean difference (95 % CI) 0.5 (−17.8, 18.9) 22.5 (4.0, 40.9)
P-valueb 0.954 0.017
Secondary outcome
3MSCT (stairs/min change from BL)
LS mean difference (95 % CI) −0.5 (−3.7, 2.8) 1.1 (−2.1, 4.4)
P-valuec 0.778 0.494
Normalised urine KS (% change from BL)
LS mean difference (95 % CI) −30.2 (−38.5, −22.0) −40.7 (−49.0, −32.4)
Tertiary outcome
MVV (% change from BL)
LS mean difference (95 % CI) 3.4 (−9.9, 16.6) 10.3 (−1.8, 22.4)
6MWD/3MSC/MVV composite z-score (change from BL)
LS mean difference (95 % C) 0.0 (−0.1, 0.2) 0.1 (−0.0, 0.3)
FVC (% change from BL)
LS mean difference (95 % CI) 3.0 (−2.4, 8.3) 3.3 (−3.1, 9.6)
FEV1 (% change from BL)
LS mean difference (95 % CI) 0.2 (−7.4, 7.9) 1.8 (−5.5, 9.2)
MPS HAQ
Self care domaind score (change from BL)
LS mean difference (95 % CI) −0.1 (−0.5, 0.3) 0.1 (−0.3, 0.5)
Caregiver assistance domaind score (change from BL)
LS mean difference (95 % CI) −0.4 (−2.4, 1.6) −0.9 (−2.8, 1.1)
Mobility domaind score (change from BL)
LS mean difference (95 % CI) −0.3 (−0.8, 0.2) −0.3 (−0.8, 0.3)
Anthropometric measures
Standing height z-scoree (change from BL)
LS mean difference (95%CI) 0.1 (−0.1, 0.3) 0.1 (−0.0, 0.3)
Growth rate z-scoree (change from BL)
LS mean difference (95 % CI) 0.4 (−0.1, 0.9) 0.4 (−0.1, 0.9)
3MSCT 3-min stair climb test; 6MWT 6-min walk test; BL baseline; CI confidence interval; FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity; HAQ health assessment questionnaire; KS keratan sulfate; LS mean least squares mean; MPS mucopolysaccharidosis; MVV maximum
voluntary ventilation; qow every other week
a Treatment effect defined as (change from baseline to week 24, elosulfase alfa)–(change from baseline to week 24, placebo)
bP-value determined by t-test from ANCOVA model (primary endpoint analysis), adjusted for baseline covariates: age group and 6-min walk test
(6MWT) category
cP-value determined by t-test ANCOVA model adjusted for baseline covariates: age group, 6MWT category, and continuous 3-min stair climb test
dMPS HAQ domain scores range from 0 to 20; decreases in domain scores (negative values) indicate improvement
e The normalised standing height (scaled as a z-score) computed using CDC normals was explored in males ≤18 years and females ≤15 years; the
combined historical and on study normalized standard height z-scores were used to compute growth rate change (scaled as z-score)
Tertiary variables that were analysed differently from those included in the table are discussed in the text
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PIIANP or CTX1 levels, which are products of increased
cartilage and bone metabolism.
Safety
Table 2 summarises treatment-emergent AEs and serious ad-
verse events (SAEs) reported for the different treatment
groups. The most frequent AEs were mild to moderate IARs
such as vomiting, pyrexia and headache, which were generally
manageable with symptomatic treatment and/or infusion rate
modification. IARs occurred in 91.5 %, 94.9 % and 89.7 % of
patients treated with placebo, elosulfase alfa 2.0 mg/kg/qow
and elosulfase alfa 2.0 mg/kg/week, respectively. All patients
who experienced an IAR received and tolerated subsequent
infusions. Hypersensitivity AEs occurred in 11.9 %, 27.1 %
and 20.7 % of patients treated with placebo, elosulfase alfa
2.0 mg/kg/qow and elosulfase alfa 2.0 mg/kg/week, respec-
tively, and were mostly mild or moderate in severity. While
22.4 % of the 58 patients receiving elosulfase alfa 2.0 mg/kg/
week group had at least 1 AE over 6 months leading to an
infusion interruption/discontinuation requiring medical atten-
tion, none withdrew or discontinued treatment due to an AE.
Also, of the 1345 total infusions administered over 6 months
to this treatment cohort, only 17 (1.3 %) were interrupted or
discontinued (14 and 3, respectively) and also required med-
ical intervention.
The percent of subjects with SAEs was 3.4 % for placebo,
6.8 % for elosulfase alfa qow and 15.5 % for elosulfase alfa
once weekly arm. The majority of SAEs in the weekly dose
group appeared to be either infusion-related, procedure-
related or Morquio A disease related. Three elosulfase alfa-
treated patients had SAEs that were considered by the
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investigator to be related to the study drug: (1) one anaphy-
lactic reaction that resolved the same day with treatment and
reduction of infusion rate (qow group), (2) one hypersensitiv-
ity reaction that resolved within 24 h with symptomatic med-
ical treatment and infusion discontinuation (weekly group)
and (3) one case of severe vomiting that resolved the same
day without medication (weekly group). None of these SAEs
led to study discontinuation. No deaths occurred on study.
All patients treated with elosulfase alfa developed anti-drug
antibodies and the majority developed antibodies capable of
interfering with CI-M6PR binding in vitro (NAb). Despite the
high incidence of anti-elosulfase alfa antibodies, decreases in
urine KS and improvements in 6MWT were observed in
treated subjects. No correlations were detected between higher
TAb titers or NAb positivity and reduced 6MWT results or
increased incidence of hypersensitivity AEs. Less than 10 %
of subjects tested positive for drug-specific IgE during the
study. Drug-specific IgE positivity was not associated with the
occurrence of anaphylaxis, other hypersensitivity AEs and/or
treatment withdrawal.
Discussion
Morquio A syndrome is a progressive and serious disorder
causing extensive morbidity and early mortality. The clinical
presentation of Morquio A is very heterogeneous, resulting in
a wide variety of specific phenotypes (Harmatz et al 2013;
Montaño et al 2007). The disease represents a significant
unmet medical need because there are currently no available
treatment options that specifically correct the biological cause
of the condition.
Individual cases of hematopoietic stem cell transplantation
(HSCT) in patients withMorquio A have been reported show-
ing some clinical benefit, but no impact on skeletal manifes-
tations (Tomatsu et al 2011; Algahim and Almassi 2013).
Considering the limited experience and the high morbidity
associated with HSCT, this therapy is currently not recom-
mended for Morquio A syndrome. The present study was
designed to determine whether ERTwith elosulfase alfa could
be a therapy for Morquio A syndrome. ERT replaces the
deficient GALNS enzyme by a functioning enzyme
(rhGALNS or elosulfase alfa), thus repairing the mechanism
for degrading keratan sulfate and chondroitin sulfate which is
believed to lie at the basis of the disease manifestations. The
dosing regimen of 2.0 mg/kg/week was selected on the basis
of data from a phase 1/2 clinical study (Hendriksz et al 2012)
evaluating dose escalation which showed greatest reduction in
urine KS at 2.0 mg/kg and on nonclinical and in vitro studies
with elosulfase alfa (Dvorak-Ewell et al 2010). A more con-
venient 2.0 mg/kg/qow dosing regimen was also evaluated to
determine whether patients could derive benefit (and a lower
risk of AEs) with less frequent dosing and lower cumulative
exposure.
While not a direct measure of the effect of treatment on
how patients feel, function or survive, the 6MWT provides an
indirect assessment of endurance and functionality (Fleming
and Powers 2012). Due to its enhanced sensitivity to treatment
effect, it has been used in a variety of patient populations,
including those with moderate to severe heart and lung dis-
eases, neurological diseases and musculoskeletal diseases
(Butland et al 1982; McDonald et al 2010). The test was first
used for registration purposes in patients with pulmonary
hypertension (Barst et al 1996). The 6MWT (or 12 MWT as
a variation) has been the primary outcome or component of a
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composite outcome in all three previously approved therapies
for MPS disease (Harmatz et al 2006; Muenzer et al 2006;
Wraith et al 2004). Although it remains unclear whether the
improvement in MPS disease is related to change in muscle
strength, joint function/pain, cardiac function or pulmonary
function or some combination of these parameters, it has been
the most useful marker of drug effect on physical function in
this population. The very short stature, severe bone and joint
abnormalities, muscle weakness and very limited lung capac-
ity in the MPS population presents a challenge in finding a
functional task that is within the capacity of patients to per-
form reliably, reproducibly and according to standardised
guidelines. The 6MWT also has been a sensitive and rapidly
responsive marker, which is essential for the short-term trials
required for MPS ERT trials because of the invasiveness of
placebo intervention (i.e. weekly iv infusions) and the high
frequency of MPS disease-related complications and
surgeries. The 6MWT has been shown to meet this challenge
in three previous MPS disease phase 3 trials, in contrast to
pulmonary function tests and a number of tertiary outcome
variables such as joint range of motion, grip and pinch
strength, coin pick-up, QoL assessments, growth and survival.
In this clinical trial in Morquio A patients, an improvement
in 6MWT distance on elosulfase alfa 2.0 mg/kg/week over
placebo began to emerge at 12 weeks and became more
apparent at week 24, where the placebo adjusted mean in-
crease in 6MWT distance was 22.5 m. While it is not possible
to specifically determine which body system was responsible
for improvement in 6MWT distance in each patient, it is likely
that it was a multifactorial effect based on the pathophysiology
of the condition. However, the difference in 6MWT distance
with placebo at 24 weeks was only 0.5 m in the elosulfase alfa
2.0 mg/kg/qow cohort. Accounting for the pre-specified ad-
justment for comparison of both regimens with placebo, the
Table 2 Overall summary of treatment-emergent adverse events (AEs) and overview of serious adverse events (SAEs). Number (%) of patients in safety
population
Placebo
(n=59)
Elosulfase alfa 2.0 mg/kg/qow
(n=59)
Elosulfase alfa 2.0 mg/kg/wee
(n=58)
Any treatment-emergent AE 57 (96.6 %) 59 (100.0 %) 56 (96.6 %)
Mild 36 (61.0 %) 33 (55.9 %) 28 (48.3 %)
Moderate 20 (33.9 %) 23 (39.0 %) 26 (44.8 %)
Severe 1 (1.7 %) 3 (5.1 %) 2 (3.4 %)
Any study drug-related AEa 36 (61.0 %) 42 (71.2 %) 42 (72.4 %)
Mild 32 (54.2 %) 27 (45.8 %) 24 (41.4 %)
Moderate 4 (6.8 %) 14 (23.7 %) 16 (27.6 %)
Severe 0 1 (1.7 %) 2 (3.4 %)
Any AE leading to dose interruption/discontinuation
requiring medical attention
0 9 (15.3 %) 13 (22.4 %)
Any AE leading to permanent study drug discontinuation 0 0 0
SAEs
At least 1 reported SAE 2 (3.4 %) 4 (6.8 %) 9 (15.5 %)
Pneumonia 0 0 2 (3.4 %)
Hypersensitivity 0 0 1 (1.7 %)
Infusion site pain 0 0 1 (1.7 %)
Lower respiratory tract infection 0 0 1 (1.7 %)
Otitis media 0 1 (1.7 %) 1 (1.7 %)
Urticaria 0 0 1 (1.7 %)
Viral upper respiratory tract infection 0 0 1 (1.7 %)
Vomiting 0 0 1 (1.7 %)
Anaphylactic reaction 0 1 (1.7 %) 0
Cervical cord compression 1 (1.7 %) 0 0
Deafness 1 (1.7 %) 0 0
Dengue fever 0 1 (1.7 %) 0
Suture removal 0 1 (1.7 %) 0
aA drug-related AE was classified by investigator as possibly or probably related to study drug
AEs and SAEs coded by MedDRAversion 15.0; maximum severity is summarised by subject
Severity categories: mild, no limitation of usual activities; moderate, some limitation of usual activities; severe, inability to carry out usual activities
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effect on the weekly regimen did meet the threshold for
statistical significance. The trial was designed to detect a
placebo-adjusted improvement of 40m. The reason the results
were not robustly positive is that the estimated effect size was
smaller.
There has not been a rigorous anchor-based assessment of
the minimally clinically important difference (MCID) for
6MWT in Morquio A or other MPS diseases. If such an
assessment could be developed, it would provide valuable
insights into the clinical relevance of a placebo-adjusted dif-
ference of 22.5 m at 24 weeks inMorquio A syndrome, which
is characterised by progressive debilitation, frequently leading
to immobility and the need for life-long assistance with activ-
ities of daily living (Harmatz et al 2013; Montaño et al 2007).
The mean screening 6MWT distance of the study population
of around 210 m is markedly lower than that of a healthy
pediatric population, ranging from 470 to 664 m (Lammers
et al 2008; Li et al 2007), and significantly lower than the 370
m in the chronic obstructive pulmonary disease population,
which provided a MCID of 54 m (Redelmeier et al 1997). A
recent study in patients with Duchenne muscular dystrophy
identified 5.9 m as the MCID for a baseline walk distance of
150 m, suggesting that smaller increases in 6MWT distance
may result in meaningful changes in QoL measurements
(Henricson et al 2013). The 22 m difference/improvement in
the present study should fit in the spectrum between these two
disease populations.
In the 3MSCT, both weekly and qow dosing groups did not
show improvement over placebo by week 24. It is unknown
why the 3MSCT results did not parallel the primary endpoint
data. 3MSCTwas included as a secondary endpoint based on
its use in previous ERT studies in MPS VI patients (Harmatz
et al 2005; Harmatz et al 2006; Harmatz et al 2008) and on
results seen in the phase 1/2 clinical trial of elosulfase alfa in
Morquio A patients (Hendriksz et al 2012). However the test
may be more variable and less suitable for Morquio A pa-
tients, who tend to show more severe skeletal dysplasia and
joint abnormalities and therefore have more ambulation diffi-
culties (walking aid and wheelchair use) than the patients
included in these MPS VI studies (Aslam et al 2013;
Harmatz et al 2013; Hendriksz et al 2013; Montaño et al
2007). Also, it may be that 24 weeks is not a long enough
observation period to detect a difference versus placebo, or
that elosulfase alfa does not provide substantial benefits on the
3MSCT in this disease setting.
Urine KS is considered a pharmacodynamic biomarker for
Morquio A syndrome, with higher levels being related tomore
severe clinical impairment (Harmatz et al 2013; Dũng et al
2013). Urine C6S was intentionally not measured as it accu-
mulates to a lesser extent than does KS as it presumably has an
alternative route for catabolism in addition to GALNS
(Neufeld and Muenzer 2001). While there was an observed
decline in urine KS on the elosulfase alfa regimens, it is
noteworthy that the relative effects of the two elosulfase alfa
regimens on the urine KS biomarker did not accurately predict
their estimated relative effects on the 6MWTat 24weeks. This
could mean that either a correlation does not exist, that the
primary clinical outcome measure did not detect such a cor-
relation with the present study sample size, or that a threshold
effect occurs for the endurance responses. More likely, the
urine KS is highly sensitive to dose changes not seen in an
endurance test impacted by multiple factors (i.e. surgeries,
neurologic injury, joint abnormalities). In our study, there
was a transient increase in urine KS at week 12 in the
elosulfase alfa 2.0 mg/kg/qow group. The reason for this
remains unclear.
The analyses of tertiary variables showed numerical im-
provements over placebo at 24 weeks in the elosulfase alfa
arms for the majority of measures. However, for all single
measures, including MVV, FVC, FEV1, growth rate, standing
height and all MPS HAQ domains, the sizes of the estimated
effects were modest. The group composite efficacy measure,
comprising 6MWT, 3MSCT, and MVV measurements,
reflected the positive trends from the 6MWT and MVV end-
points but, due to small effects on 3MSCT, failed to achieve
significance.
Treatment compliance was high and almost all pa-
tients completed the study without treatment discontin-
uation. The safety profile of elosulfase alfa was gener-
ally similar to that of other ERTs (e.g. MPS I, II and
VI) (Clarke et al 2009; Harmatz et al 2008; Muenzer
et al 2006; Muenzer et al 2011). The most common side
effects of elosulfase alfa were IARs, which were self-
limiting and manageable with symptomatic treatment.
The high rate of IARs was not unexpected for treat-
ments with recombinant protein. Infusion reactions re-
quiring dose interruption/discontinuation and also requir-
ing medical attention were observed in 22.4 % of pa-
tients, but in only 1.3 % of all infusions given to the
weekly dose group over the 24 weeks of the study.
None of these IARs led to permanent study drug dis-
continuation. The percent of subjects with SAEs was
approximately four-fold higher on the once weekly reg-
imen than on placebo. A majority of the SAEs in the
weekly dose group were either infusion-related, surgical
procedure-related, or disease-related.
All patients receiving elosulfase alfa developed anti-
elosulfase alfa antibodies. Although it is not possible to deter-
mine whether this had an effect on the magnitude of the
efficacy responses or on the incidence of hypersensitivity
AEs, it is of interest that neither total antibody titres nor
NAb positivity were associated with hypersensitivity AEs.
The present study is the largest placebo-controlled trial
conducted to date in MPS patients and has generated a rea-
sonable safety database for this ultra-rare disease. The impact
of elosulfase alfa on 6MWT distance and urine KS levels
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shows that the therapy indeed has the potential to correct the
biological cause of Morquio A syndrome. However, the pro-
gressive nature of the disease warrants more, longer-term
studies to assess how the therapy will influence the disease
course in the long term, especially when ERT can be started
before severe manifestations have developed.
The study population of the present study can be
considered representative of the general Morquio A
population. However, as the study did not include pa-
tients unable to walk or with near-normal endurance in
a 6MWT during screening and no patients below 5 years
of age, no conclusions can currently be made regarding
the impact of elosulfase alfa on 6MWT distance in
these patients. Other clinical trials including these pa-
tient populations are currently ongoing. Nevertheless,
the patients in this study exhibited a wide spectrum of
age, disease severity and clinical manifestations, with
mean 6MWT, 3MSCT and pulmonary function data
being comparable to those reported in the MorCAP
study (Harmatz et al 2013). The very complete, robust
and high quality data collected during the study and the
consistency of duplicate test results in 6MWT (intraclass
correlation coefficient [ICC] range 0.868-0.938 by visit
and regimen) and 3MSCT (ICC range 0.881-0.968)
assessments enhance the validity of the findings. The efforts
made to maximise data quality resulted in a very high dosing
compliance, with only 0.6-1.8 % of planned infusions missed,
and a very low number of missing efficacy data points. Only
two week 24 6MWT assessments were missed.
Conclusions
In this double-blind, randomised, placebo-controlled pivotal
phase 3 study in Morquio A patients, the pre-specified prima-
ry efficacy measure of 6MWT distance at 24 weeks improved
in the elosulfase alfa 2.0 mg/kg weekly, but not the qow dose
group. Both elosulfase alfa regimens did not improve endur-
ance in the 3MSCT, but did lead to a reduction in urine KS.
These regimens were shown to provide generally safe ERT for
patients with Morquio A syndrome. Elosulfase alfa may pres-
ent a new treatment for patients with Morquio A who have
currently no medical care option other than symptomatic
therapy of disease complications.
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